SynthesisBMC infectious diseases2025
Extended spectrum beta-lactamase and carbapenemase-producing Acinetobacter species and Pseudomonas aeruginosa in Ethiopia: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtended spectrum beta-lactamases (ESBLs) and carbapenemase producing Acinetobacter baumannii and Pseudomonas aeruginosa are the top antibiotic-resistant priority list of pathogens representing the greatest threat to human health. However, their exact magnitude was not well known. Thus, the aim of this study was to evaluate the magnitude of ESBL and carbapenemase-producing Acinetobacter baumannii and Pseudomonas aeruginosa in Ethiopia.
methodsArticles were extensively searched in bibliographic databases and grey literatures using entry terms or phrases. Studies meeting eligibility criteria were extracted in MS Excel and exported into STATA version 11 software for statistical analysis. A random-effects model was used to compute the pooled prevalence of ESBL and carbapenemase-producing A. baumannii and P. aeruginosa clinical isolates. The heterogeneity was quantified by using the I2 value. Publication bias was assessed using a funnel plot and Egger’s test. Sensitivity analysis was done to assess the impact of a single study on pooled effect size.
resultOf the 853 studies identified, 17 studies were eligible for qualitative analysis. A total of 17 studies of P.aeruginosa and 13 A.baumannii studies were included for meta-analysis consisted of 542 and 372 isolates were P. aeruginosa and A. baumannii, respectively. The overall pooled prevalence of ESBL and carbapanamase producing A. baumannii and/or P. aeruginosa in Ethiopia was 34% (95%CI: 30–38). The pooled prevalence of ESBL producing A. baumannii and P. aeruginosa was 23% (95%CI: 21–25) and 38% (95%CI: 4–72), respectively. Likewise, the pooled prevalence of carbapenemase-producing A. baumannii and P. aeruginosa was 36% (95%CI: 29–42) and 25% (95%CI; 20–31), respectively. There was substantial heterogeneity. Additionally, the pooled prevalence of multi-drug resistant A. baumannii and P. aeruginosa isolates was 77% (95% CI: 66–87) and 68% (95% CI: 50–86), respectively.
conclusionESBL and carbapenemase-producing A. baumannii and P. aeruginosa was highly prevalent among clinical samples of Ethiopian populations. The initial empirical treatment of these patients remains challenging because of the strikingly high prevalence of antimicrobial resistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.